Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
2024 · New England Journal of Medicine · 160 citations
https://doi.org/10.1056/nejmoa2412006
J
Jing Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
391
Papers
6.3K
Citations
40
h-index
126
i10-index
Jing Wang is an academic researcher from Shihezi University. The author has contributed to research in topics: Cancer-related Molecular Pathways & Advanced Breast Cancer Therapies & Heat shock proteins research. The author has an h-index of 40, co-authored 333 publications.
ORCID: 0000-0002-3224-3993Papers by this author
worksA serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
2018 · Nature Communications · 103 citations
https://doi.org/10.1038/s41467-018-03537-w
Blockade of EGFR and ErbB2 by the Novel Dual EGFR and ErbB2 Tyrosine Kinase Inhibitor GW572016 Sensitizes Human Colon Carcinoma GEO Cells to Apoptosis
2006 · Cancer Research · 96 citations
https://doi.org/10.1158/0008-5472.can-05-2506
TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation
2022 · Journal of Experimental & Clinical Cancer Research · 74 citations
https://doi.org/10.1186/s13046-022-02252-1
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)
2025 · American Heart Journal · 63 citations
https://doi.org/10.1016/j.ahj.2025.03.019
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
2024 · Journal of Clinical Oncology · 54 citations
https://doi.org/10.1200/jco.23.01500
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat